Related Experiment Video
Updated: May 11, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Oral anticoagulant therapies: balancing the risks
1College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA. enutescu@uic.edu
Summary
Warfarin and newer oral anticoagulants require careful management to balance bleeding and clotting risks. Individualized strategies are essential for patients undergoing procedures, considering drug, patient factors, and validated risk assessments.
Area of Science:
- Pharmacology and Therapeutics
- Cardiovascular Medicine
Background:
- Warfarin and target-specific oral anticoagulants (TSOACs) are crucial for preventing thromboembolism.
- Understanding their mechanisms, pharmacokinetics, and bleeding risks is vital for safe use.
Purpose of the Study:
- To review warfarin and TSOACs regarding action, pharmacokinetics, and bleeding.
- To outline methods for assessing thromboembolic and bleeding risks during interruptions for procedures.
- To discuss strategies for balancing these risks and monitoring therapies.
Main Methods:
- Literature review and synthesis of data on oral anticoagulants.
- Analysis of risk assessment tools for thromboembolism and bleeding.
- Discussion of therapeutic strategies and coagulation monitoring.
Main Results:
- TSOACs offer specific mechanisms and shorter half-lives than warfarin, but accumulation risk exists in renal impairment/elderly.
- Community bleeding rates may exceed clinical trial data.
- Validated risk scores are necessary for patient stratification.
Conclusions:
- Balancing thromboembolic and bleeding risks requires individualized approaches.
- Management of oral anticoagulants around procedures depends on drug, procedure type, and patient variables (especially renal function).
- Novel coagulation assays are under development for monitoring.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...